Rivers Jason K, Rosoph Les, Provost Nathalie, Bissonnette Robert
Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada.
J Cutan Med Surg. 2008 May-Jun;12(3):97-101. doi: 10.2310/7750.2008.07045.
Local skin reactions are common during imiquimod treatment of actinic keratosis (AK). Cyclical application of imiquimod may improve tolerability while maintaining efficacy.
To assess the tolerability of imiquimod and clearance rate of AK lesions after imiquimod application.
Imiquimod 5% cream was administered three times per week for 4 weeks followed by 4 weeks of rest (cycle 1) to AK lesions on the head. If AK lesions remained visible at the end of cycle 1, a second treatment cycle was instituted.
Fifty percent (30 of 60) of patients experienced complete clearance of AK lesions, and 75% (30 of 40) of patients experienced partial clearance of AK lesions after imiquimod treatment at the end of cycle 2. Moreover, 77% of patients who achieved complete clearance had no visible AK lesions 12 weeks post-treatment. Imiquimod was well tolerated.
Imiquimod cycle therapy may be a safe and effective treatment option for AK lesions.
在光化性角化病（AK）的咪喹莫特治疗过程中，局部皮肤反应很常见。周期性应用咪喹莫特可能会提高耐受性，同时保持疗效。
评估咪喹莫特的耐受性以及应用咪喹莫特后AK皮损的清除率。
将5%咪喹莫特乳膏每周给药3次，持续4周，随后休息4周（第1周期），用于治疗头部的AK皮损。如果在第1周期结束时AK皮损仍可见，则开始第2个治疗周期。
在第2周期结束时，50%（60例中的30例）的患者AK皮损完全清除，75%（40例中的30例）的患者AK皮损部分清除。此外，77%实现完全清除的患者在治疗后12周没有可见的AK皮损。咪喹莫特耐受性良好。
咪喹莫特周期疗法可能是治疗AK皮损的一种安全有效的选择。
